Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides

Alexander S Vedenkin1, Sergey V Stovbun2, Alexander A Bukhvostov3

  • 1N.N. Semenov Federal Research Center for Chemical Physics RAS, Moscow, Russia. a.s.vedenkin@gmail.com.

Investigational New Drugs
|February 7, 2023
PubMed

Insights

Ultra-short single-stranded deoxyribose polynucleotides (ssDNA) show promise as novel anti-cancer drugs. These compounds effectively inhibit DNA polymerase, suppressing cancer cell proliferation and tumor growth in preclinical studies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Cancer cells exhibit increased proliferation rates, presenting a therapeutic target.
  • DNA replication and repair are critical for cell survival and proliferation.
  • Inhibiting DNA replication machinery can lead to cancer cell death.

Purpose of the Study:

  • To investigate the anti-tumor potential of ultra-short single-stranded deoxyribose polynucleotides (ssDNA).
  • To evaluate the efficacy of ssDNA in inhibiting DNA polymerase activity.
  • To assess the therapeutic effects of ssDNA on cancer development and tumor growth.

Main Methods:

  • In vitro studies using cancer cell cultures.
  • In vivo studies using mouse cancer models.
  • Assay of DNA polymerase catalytic activity inhibition by ssDNA.

Main Results:

  • ssDNA effectively inhibits the catalytic activity of DNA polymerase.
  • ssDNA demonstrated significant suppression of cancer development in vitro.
  • ssDNA significantly suppressed tumor growth in vivo mouse models.

Conclusions:

  • Ultra-short single-stranded deoxyribose polynucleotides are effective inhibitors of DNA polymerase.
  • ssDNA exhibits significant anti-tumor activity, warranting further investigation as a novel cancer therapeutic agent.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
Single-Strand DNA Binding Proteins01:03

Single-Strand DNA Binding Proteins

For successful DNA replication, the unwinding of double-stranded DNA must be accompanied by stabilization and protection of the separated single strands of the DNA. This crucial task is performed by single-strand DNA-binding (SSB) proteins. They bind to the DNA in a sequence-independent manner, which means that the nitrogenous bases of the DNA need not be present in a specific order for binding of SSB proteins to it. The binding of SSB proteins straightens single-stranded DNA (ssDNA) and makes...
14.5K